Pelacarsen: The First Drug That Could Prove Lowering Lp(a) Saves Lives — Inside the Landmark Lp(a)HORIZON Readout (August 5, 2026)
Table of Contents
The risk factor hiding in plain sight
Most people have never heard of lipoprotein(a), usually written Lp(a) and said aloud as 'L-P-little-a.' Yet roughly one in five people worldwide inherit high levels of it, and it is one of the most important causal drivers of heart attack, stroke, peripheral artery disease, and calcific aortic valve stenosis. What makes Lp(a) so frustrating is that it is set almost entirely by your genes. It does not budge with diet or exercise, and it is essentially untouched by the two pillars of modern cholesterol care — statins and PCSK9 inhibitors. You can drive someone's LDL cholesterol to the floor and still leave a dangerous Lp(a) level completely intact. Until now there has been no approved drug that lowers it specifically.
What pelacarsen is
Pelacarsen (formerly IONIS-APO(a)-LRx and TQJ230) is a once-monthly injectable antisense oligonucleotide — a short, engineered strand of genetic material rather than a classic peptide or antibody. It was discovered by Ionis Pharmaceuticals using its LICA (Ligand-Conjugated Antisense) platform, in which the drug is tagged with a sugar called GalNAc that acts like a homing beacon for liver cells. Once inside the liver, pelacarsen binds the messenger RNA for apolipoprotein(a) — the protein that defines the Lp(a) particle — and marks it for destruction. With less apo(a) being made, the liver assembles far fewer Lp(a) particles. Novartis licensed the drug from Ionis in 2019 for worldwide development.
How well does it lower Lp(a)?
Very well. In Phase 2 testing, monthly pelacarsen produced dose-dependent reductions in Lp(a) of up to about 80%, and the 80 mg monthly dose chosen for the pivotal trial pushed 98% of participants below the 50 mg/dL threshold that guidelines treat as the line for elevated cardiovascular risk. In other words, the drug reliably does the one thing nothing else can: it takes a genetically 'fixed' risk factor and moves it dramatically. The open question was never whether pelacarsen lowers Lp(a) — it clearly does — but whether that lowering actually prevents heart attacks and strokes.
Lp(a)HORIZON: the experiment the whole field is waiting on
That question is exactly what the Phase 3 Lp(a)HORIZON trial (NCT04023552) was built to answer. It enrolled 8,323 patients with established cardiovascular disease and Lp(a) at or above 70 mg/dL into a global, randomized, double-blind, placebo-controlled study, testing whether 80 mg of pelacarsen once a month reduces major adverse cardiovascular events — a composite of cardiovascular death, non-fatal heart attack, non-fatal stroke, and urgent coronary revascularization. Here is why it matters far beyond a single drug: Lp(a)HORIZON is the first cardiovascular outcomes trial ever conducted for any Lp(a)-lowering therapy. Its result will test the central hypothesis of the entire field.
Why this is bigger than one molecule
Pelacarsen is the front-runner, but it is not alone. A cluster of Lp(a)-lowering drugs is right behind it, most of them small interfering RNAs (siRNAs): Amgen's olpasiran, Eli Lilly's lepodisiran, and Silence Therapeutics' zerlasiran, some of which lower Lp(a) by more than 90%. All of them rest on the same unproven premise — that lowering Lp(a) will translate into fewer cardiovascular events. Because pelacarsen's outcomes trial reads out first, it effectively serves as the proof-of-concept for the whole class. A clearly positive result would validate Lp(a) as a modifiable target and likely accelerate every program behind it; a disappointing one would force a hard rethink.
Where the readout stands
Topline results were originally guided for 2025 and then to a window around the middle of 2026. As of mid-2026 the trial is fully enrolled and the readout is imminent but not yet public, which is why pelacarsen sits at the very top of cardiology's watch list for the year. Novartis has said regulatory submissions would follow a positive readout. Because this is an event-driven outcomes trial, the exact timing depends on when enough cardiovascular events have accrued — a reminder that even a fully enrolled landmark trial reports on biology's schedule, not the calendar's.
The bottom line
Pelacarsen is an investigational, once-monthly antisense oligonucleotide from Ionis and Novartis that lowers lipoprotein(a) by roughly 80% by shutting down apolipoprotein(a) production in the liver. It is not approved anywhere, and it is a prescription clinical-stage medicine — not a supplement or research chemical; anything sold under the names 'pelacarsen,' 'TQJ230,' or 'apo(a)-LRx' by a vendor is unverified. Its Lp(a)HORIZON trial is the first outcomes study to ask whether lowering Lp(a) prevents heart attacks and strokes, and its 2026 readout is one of the most consequential events in preventive cardiology in years — for the drug itself and for the emerging Lp(a)-lowering class that includes olpasiran, lepodisiran, and zerlasiran.
Ready to track your peptide research?
Open PepTracker ProPepTracker Pro Research Team
The PepTracker Pro Research Team is an editorial group of science writers, pharmacologists, and clinical researchers dedicated to making peptide science accessible. Every article is reviewed for accuracy against peer-reviewed sources and updated as new evidence emerges.
Citations
- [1] Ionis — Enrollment Completion of Phase 3 Lp(a)HORIZON Cardiovascular Outcomes Study of Pelacarsen Source
- [2] Lp(a)HORIZON — Effect of Lipoprotein(a) Lowering With Pelacarsen on Major Cardiovascular Events (ClinicalTrials.gov NCT04023552) Source
- [3] Lipoprotein(a): An Independent Risk Factor for CV Disease — American College of Cardiology Source
- [4] 2026 Cardiovascular Catalysts: Lp(a) on the Horizon — BioCentury Source
Related Articles
A landmark Nature paper introduces the first quintuple receptor agonist (GLP-1/GIP/PPARα/γ/δ) for obesity, GDF-15 receptor agonists gain momentum as a non-GLP-1 weight loss mechanism, and apelin/APJ cardiovascular peptides advance toward clinical candidates.
Sotatercept (Winrevair): The Activin Trap That Made Pulmonary Arterial Hypertension a Treatable Disease, Not Just a Managed One (July 18, 2026)
Merck's sotatercept (Winrevair) is a fusion protein that traps activin A, activin B, myostatin and GDF-11 - and it changed what pulmonary arterial hypertension therapy can aim for. STELLAR delivered a 40.8-meter gain in 6-minute walk distance; ZENITH cut death, transplant and hospitalization by 76% in the sickest patients and led to an expanded FDA label on October 27, 2025. Here is how the broadest activin-axis drug compares with the selective antibodies chasing the same biology.
WVE-007: Silencing a Fat-Storage Gene to Lose Fat Without Losing Muscle (July 29, 2026)
Most obesity drugs work on appetite. WVE-007 goes after the fat cell itself - it's a single-shot siRNA that silences INHBE, the liver gene behind the hepatokine Activin E, to release the brake on fat burning. In Wave's Phase 1 INLIGHT trial one dose cut visceral fat while lean mass held or rose, hinting at muscle-sparing weight loss and once- or twice-yearly dosing.